Rocket Pharmaceuticals (RCKT) Registration Filing summary

Company overview and business model

• Fully integrated, late-stage biotechnology company developing gene therapies for rare and fatal diseases with high unmet medical need.

• Focused on genetic therapies for inherited cardiomyopathies and related disorders, leveraging a multi-platform approach.

• Operates in-house cGMP manufacturing facilities, enabling end-to-end control from R&D to potential commercialization.

• Strategic reorganization in July 2025 prioritized AAV cardiovascular gene therapy platform and reduced workforce by 30%, aiming to extend operational runway and reduce expenses by 25%.

• Holds global commercialization and development rights to all current product candidates under internal IP and license agreements.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, clinical development, commercialization planning, working capital, and capital expenditures.

• Proceeds may be temporarily invested in short-term, investment-grade instruments or held as cash until used.

• Management retains broad discretion over allocation of net proceeds.

Risk factors and disclosures

• Investment involves a high degree of risk, including potential adverse effects on business, financial condition, or results if risks materialize.

• Risks include ability to obtain funding, regulatory approvals, competition, clinical trial outcomes, and IP protection.

• Forward-looking statements are subject to uncertainties and actual results may differ materially.